RG
TLIS icon

Redmile Group’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Redmile Group’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,257
Closed -$4.01M – 89
2021
Q2 		$4.01M Sell
24,257
-2,410
-9% -$409K 0.06% 81
2021
Q1 		$5.14M Buy
+26,667
New +$6.65M 0.07% 80

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Redmile Group's TLIS Position: Q3 2021 in Review

Redmile Group sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2021, closing a stake of 24,257 shares — an estimated $4.01M sold.

Redmile Group first reported a position in TLIS in Q1 2021 and held it in 2 quarters. The position peaked at $5.14M in Q1 2021. 38 funds tracked by Wall St. Rank hold TLIS as of Q3 2021.

  • Redmile Group reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Redmile Group sold 24,257 Talis Biomedical Corporation Common Stock shares in Q3 2021, an estimated $4.01M.
  • Redmile Group first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 2 quarters.
  • Redmile Group's Talis Biomedical Corporation Common Stock position peaked at $5.14M in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2021.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.